VBL Therapeutics is pinning its hopes on a preclinical anti-inflammatory program after its lead gene therapy candidate for ovarian cancer, ofra-vec (ofranergene obadenovec, VB-111), flunked the Phase III OVAL trial.
VBL’s stock dropped by 79% pre-market on the NASDAQ upon announcement of the news, as doubts were raised about the product's other indications and the firm has little else in its pipeline
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?